Evommune director trust buys 10K shares

Evommune, Inc. director Arthur S. Kirsch reported an indirect open-market purchase of 10,000 shares of common stock at a weighted average price of $13.30 per share.

Rhea-AI Filing Summary

Evommune, Inc. director Arthur S. Kirsch reported an indirect open-market purchase of 10,000 shares of common stock at a weighted average price of $13.30 per share. The shares are held by a family trust for which he is a trustee, and he disclaims beneficial ownership except for his proportionate pecuniary interest.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider KIRSCH ARTHUR S

Role Director

Bought 10,000 shs ($133K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$13.30	$133K

Holdings After Transaction: Common Stock — 10,000 shares (Indirect, By Trust)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Key Figures

Shares purchased: 10,000 shares Weighted average price: $13.30 per share Price range: $13.25–$13.35 per share +1 more

4 metrics

Shares purchased 10,000 shares Open-market common stock purchase

Weighted average price $13.30 per share Reported transaction price

Price range $13.25–$13.35 per share Individual trade prices in the purchase

Shares held after transaction 10,000 shares Indirect ownership by family trust

Key Terms

weighted average price, family trust, beneficial ownership, open-market purchase

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

family trust financial

"The securities are held by a family trust, of which the Reporting Person is a trustee."

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Evommune (EVMN) report for Arthur S. Kirsch?

Evommune reported that a family trust associated with director Arthur S. Kirsch bought 10,000 shares of common stock in an open-market transaction. The filing shows this as an indirect purchase at a weighted average price of $13.30 per share.

At what price were the Evommune (EVMN) shares purchased in this Form 4?

The reported weighted average purchase price was $13.30 per share. Footnotes explain the 10,000 shares were bought in multiple trades at prices ranging from $13.25 to $13.35 per share during the same transaction date.

How many Evommune (EVMN) shares does the trust hold after this transaction?

After the reported transaction, the family trust associated with Arthur S. Kirsch holds 10,000 Evommune common shares. The Form 4 lists this as the total number of shares indirectly owned following the open-market purchase disclosed.

Is Arthur S. Kirsch the direct owner of the Evommune (EVMN) shares in this filing?

No, the shares are held by a family trust where he serves as trustee. The filing states he disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest in the trust’s holdings.

What does the weighted average price mean in the Evommune (EVMN) Form 4 transaction?

Weighted average price means the 10,000 shares were bought through multiple trades at slightly different prices. The filing notes individual trades ranged from $13.25 to $13.35, with $13.30 per share reported as the weighted average purchase price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 08:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIRSCH ARTHUR S

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		P		10,000	A	$13.3(1)	10,000	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)